
Conference Coverage
about 13 hours ago
What to Expect at Maui Derm NP+PA Fall 2026about 18 hours ago
Cutaneous Oncology FAQ: Practical Answers From Prevention to TreatmentLatest News

Patidegib Gel Completes Phase 3 Follow-Up in Gorlin Syndrome

Targeted Skincare, Dermabrasion Show Skin Quality Improvements During Medical Weight Loss

Two-Year POETYK PsA-2 Data Show Durable Deucravacitinib Responses in Psoriatic Arthritis

Cutaneous Oncology FAQ: Practical Answers From Prevention to Treatment

Neutrogena Launches New Sunscreens With Newly Permitted UV Filter Bemotrizinol
Videos

Shorts










Podcasts
Dermatology Times Digital Edition








All News

Longer treatment duration was independently associated with VASI improvement, while publicly insured patients experienced higher topical JAK inhibitor denial rates.

Though convenient, SPF-infused cosmetics rarely deliver their labeled protection level in real-world use, underscoring the continued need for a dedicated broad-spectrum sunscreen as the foundation of any routine.

This review of the latest dermatological studies includes insights on stem cell therapies for skin rejuvenation, smoke exposure in HS, hair loss in pediatric IBD, and more.

Genetic study links higher BMI to looking older, but causality stays unclear; Mendelian randomization flags shared signals and candidate genes needing validation.

An HS toolbox with wound care, symptom relief, and personal care supplies can help patients stay prepared for unexpected flares.

Dermatitis-related adverse events vary widely across atopic dermatitis systemic trials, driven by disease fluctuation and reporting differences, informing patient counseling and flare definitions.

The FDA has set a PDUFA target action date of June 29, 2027, based on APEX trial data showing a 65% overall response rate in advanced systemic mastocytosis.

Victoria Werth, MD, professor of dermatology and rheumatology at the University of Pennsylvania, recently discussed brepocitinib's FDA approval for dermatomyositis and what the VALOR trial data mean for patients and clinicians.

The inaugural workshop explored skin cancer care from prevention and diagnosis through systemic therapy, radiation, and multidisciplinary management.

New review explores why eczema and ADHD often overlap in youth, highlighting sleep loss, itch-driven inflammation, plus screening and treatment tips.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.

The expanded indication makes Ameluz with RhodoLED the first FDA-approved photodynamic therapy for the treatment of a skin cancer.

Takeda’s investigational oral TYK2 inhibitor is supported by phase 3 LATITUDE data demonstrating significant skin clearance versus placebo and apremilast.

The final session of the Cutaneous Oncology Workshop explored advances in systemic therapy, management of immunotherapy-related skin reactions, and the role of radiation.

Merz Aesthetics adds two FDA-approved Belotero HA fillers for midface volume and lip fullness, promising natural movement and long-lasting results.























